ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement

ERS Genomics & Demeetra Enter Into CRISPR/Cas9 Licensing Agreement
Demeetra to broaden synthetic biology and bioprocessing technology through combined CRISPR/Cas9 IP and Demeetra’s own dimeric Cas-CLOVER.

Dublin, Ireland and Kentucky, USA, September 12: ERS Genomics Limited (‘ERS’) is pleased to announce a new license agreement with Demeetra AgBio (‘Demeetra’). This is a non-exclusive licensing agreement granting Demeetra access to the ERS CRISPR/Cas9 patent portfolio which is sublicensable when combined with Cas-CLOVER.

ERS founder, Dr. Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9. The ERS patent portfolio is the definitive collection of proprietary rights to this gene editing technology.


Demeetra, headquartered in Kentucky, is a biotechnology company whose core focus is developing and optimizing gene editing technologies in commercially applicable systems.  Demeetra’s technologies and know-how are transferred to its partners through simple commercial licenses with freedom to operate.

Commenting on the deal, Jack Crawford, CEO of Demeetra stated: “We’re excited about the ERS license, granting us access to the CRISPR IP portfolio; synergizing perfectly with our dimeric Cas-CLOVER. This powerful combination will be available for sublicensing in bioprocessing and synthetic biology applications.”

Eric Rhodes, CEO, ERS Genomics was equally positive about the new licensee: “Demeetra’s commitment to enabling scientific advancement harmonizes seamlessly with our mission to broaden the use of CRISPR/Cas9. By enhancing and expanding CRISPR/Cas9 accessibility, Demeetra is driving us closer to achieving our technology’s full potential.’


Financial details of the agreement are not being disclosed.